SCHEMBL7648974

SCHEMBL7648974

CN1C(=O)CN(C(=O)OCc2ccccc2)C1C(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.48
PDK1 Q15118 1/20 0.47
PDK2 Q15119 1/20 0.47
PDK3 Q15120 1/20 0.47
PDK4 Q16654 1/20 0.47
PSEN1 P49768 1/20 0.46
PSEN2 P49810 1/20 0.46
APH1B Q8WW43 1/20 0.46
NCSTN Q92542 1/20 0.46
APH1A Q96BI3 1/20 0.46
PSENEN Q9NZ42 1/20 0.46
USP2 O75604 1/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
F2 P00734 2/20 0.42
ELANE P08246 2/20 0.42
AGTR2 P50052 1/20 0.42
PARP1 P09874 1/20 0.42
CTSG P08311 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25911018 1.00 HTR2C (0.48) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL4693326 0.76 HTR2C (0.52) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL5517082 0.75 HTR2C (0.64) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL10053573 0.75 HTR2C (0.64) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL5517077 0.75 HTR2C (0.64) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL28956425 0.75 PSEN1 (0.46) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL14209521 0.75 HTR2C (0.57) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL31114244 0.75 HTR2C (0.57) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL2249043 0.73 HTR2C (0.52) HTR2CPDK1PDK2PDK3PDK4
SCHEMBL21872248 0.73 HTR2C (0.55) HTR2CPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6117223-A Hot melt inks containing polyketones XEROX CORPORATION (US) 2000-09-12 US claimed
EP-4219511-A1 INTERMEDIATE, PREPARING METHOD THEREOF, AND METHOD OF PREPARING DRUG Heron Neutron Medical Corp. (TW) 2023-08-02 EP disclosed
US-20230234973-A1 INTERMEDIATE, PREPARING METHOD THEREOF, AND METHOD OF PREPARING DRUG HERON NEUTRON MEDICAL CORP. (TW) 2023-07-27 US disclosed
US-6461417-B1 Ink compositions XEROX CORPORATION 2002-10-08 US disclosed
US-6117223-A Hot melt inks containing polyketones XEROX CORPORATION (US) 2000-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234973-A1 INTERMEDIATE, PREPARING METHOD THEREOF, AND METHOD OF PREPARING DRUG CYP2F1, SULT1A1, CYP4F3 HTR2C 2536/4885PDK1 3737/4885PDK2 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.